Quantum-Si Reports Q3 2025 Revenue Decline and Increased Net Loss

Quantum-Si Incorporated reported its financial results for the third quarter of 2025, revealing a total revenue of $552,000, a decrease of 29.9% compared to $787,000 in the same period last year. For the nine months ending September 30, 2025, revenue increased by 6.4% to $1.985 million from $1.866 million in 2024. The company experienced a net loss of $35.7 million for the quarter, compared to a loss of $25.3 million in the prior year, and a net loss of $83.7 million for the nine months, up from $67.9 million in 2024. The increase in losses was attributed to higher operating expenses, including a significant lease termination expense of $13.6 million related to a settlement agreement for a New Haven, Connecticut lease.

In terms of operational metrics, Quantum-Si's product revenue for the third quarter was $505,000, down 33.9% from $764,000 in the previous year, while service revenue rose to $47,000 from $23,000. The company noted that longer capital sales cycles, particularly due to budget constraints at the National Institutes of Health (NIH), impacted product sales. However, for the nine-month period, product revenue increased by 5.3% year-over-year, indicating some resilience in its commercial efforts.

Strategically, Quantum-Si has been focusing on its product development roadmap, which includes the recent launch of its Platinum Pro benchtop sequencer in early 2025. The company is also preparing for the anticipated launch of its next-generation platform, Proteus, expected in the second half of 2026. The restructuring efforts initiated in late 2024, which resulted in a 23% reduction in workforce, are aimed at streamlining operations and aligning resources for future product development.

As of September 30, 2025, Quantum-Si reported total assets of $260.1 million, with cash and cash equivalents amounting to $30.9 million, down from $49.2 million at the end of 2024. The company has also raised significant capital through equity offerings, including $93.5 million from direct equity and pre-funded warrant offerings in 2025. Management believes that the current cash reserves, along with anticipated revenue, will be sufficient to fund operations for at least the next twelve months. However, the company continues to face challenges in achieving profitability and may need to rely on additional financing to support its ongoing commercialization and development efforts.